TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients

Background: Toll-like receptor-3 (TLR3) is a cellular receptor that may recognize double-stranded RNA (dsRNA) from viruses, resulting in production of proinflammatory cytokines and interferons, which are important for the adaptive immune response. Objectives: To analyze the association between Toll-...

Descripción completa

Detalles Bibliográficos
Autores: Jimenez-Sousa, Maria Angeles, Rallón, Norma, Berenguer, Juan, Pineda-Tenor, Daniel, López, Juan Carlos, Soriano, Vicente, Guzman-Fulgencio, Maria, Cosín, Jaime, Retana, Diana, Garcia-Alvarez, Monica, Miralles, Pilar, Benito, Jose Miguel, Resino, Salvador
Tipo de recurso: artículo
Fecha de publicación:2015
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19511
Acceso en línea:http://hdl.handle.net/20.500.12105/19511
Access Level:acceso abierto
Palabra clave:Adult
Alleles
Antiviral Agents
Coinfection
Female
Genotype
HIV Infections
Haplotypes
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
Male
Middle Aged
Multivariate Analysis
Polymorphism, Single Nucleotide
Retrospective Studies
Ribavirin
Toll-Like Receptor 3
id ES_df490a5b52ee5a99a30ea337d0975b68
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/19511
network_acronym_str ES
network_name_str España
repository_id_str
spelling TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patientsJimenez-Sousa, Maria AngelesRallón, NormaBerenguer, JuanPineda-Tenor, DanielLópez, Juan CarlosSoriano, VicenteGuzman-Fulgencio, MariaCosín, JaimeRetana, DianaGarcia-Alvarez, MonicaMiralles, PilarBenito, Jose MiguelResino, SalvadorAdultAllelesAntiviral AgentsCoinfectionFemaleGenotypeHIV InfectionsHaplotypesHepacivirusHepatitis C, ChronicHumansInterferon-alphaMaleMiddle AgedMultivariate AnalysisPolymorphism, Single NucleotideRetrospective StudiesRibavirinToll-Like Receptor 3Background: Toll-like receptor-3 (TLR3) is a cellular receptor that may recognize double-stranded RNA (dsRNA) from viruses, resulting in production of proinflammatory cytokines and interferons, which are important for the adaptive immune response. Objectives: To analyze the association between Toll-like receptor-3 (TLR3) polymorphisms (rs3775291 and rs13126816) and virologic response to pegylated interferon-alpha plus ribavirin (pegIFNα/RBV) therapy in HIV/HCV coinfected patients. Study design: We performed a retrospective study in 321 naïve patients treated with pegIFNα/RBV. Genotyping was performed by using the GoldenGate(®) assay with VeraCode(®). The outcome variables were early virologic response (EVR) and sustained virologic response (SVR). Results: In a multivariate analysis, rs3775291 A allele decreased the likelihood of achieving EVR (aOR = 0.20; p = 0.018) and SVR (aOR = 0.38; p = 0.024). Regarding rs13126816, the percentage of EVR decreased with each minor A allele (p = 0.034) in HCV-GT2/3 patients, although no significant association was obtained in the multivariate analysis (p = 0.076). Regarding TLR3 haplotypes (comprised of rs3775291 and rs13126816), GT2/3 patients with AA haplotype had decreased odds of achieving EVR (p = 0.030), whereas GG haplotype increased the likelihood (p = 0.018). Regarding SVR, GG haplotype carriers had increased odds of achieving SVR (p = 0.019, p = 0.043 and p = 0.070 for all, GT2/3 and GT1/4 patients, respectively). Besides, GT1/4 patients with GA haplotype had lower odds of achieving SVR (p = 0.039). Conclusions: Our study shows the first evidence that two TLR3 polymorphisms (rs3775291 and rs13126816) seem to be related to the HCV therapy response in HCV/HIV coinfected patients.ElsevierInstituto de Salud Carlos IIIRETICS-Sida (RIS-ISCIII) (España)Fundación para la Investigación y la Prevención del Sida en España20242024-05-2120152015-04-0120152015-04-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/19511reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/195112026-06-12T12:43:37Z
dc.title.none.fl_str_mv TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
title TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
spellingShingle TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
Jimenez-Sousa, Maria Angeles
Adult
Alleles
Antiviral Agents
Coinfection
Female
Genotype
HIV Infections
Haplotypes
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
Male
Middle Aged
Multivariate Analysis
Polymorphism, Single Nucleotide
Retrospective Studies
Ribavirin
Toll-Like Receptor 3
title_short TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
title_full TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
title_fullStr TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
title_full_unstemmed TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
title_sort TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients
dc.creator.none.fl_str_mv Jimenez-Sousa, Maria Angeles
Rallón, Norma
Berenguer, Juan
Pineda-Tenor, Daniel
López, Juan Carlos
Soriano, Vicente
Guzman-Fulgencio, Maria
Cosín, Jaime
Retana, Diana
Garcia-Alvarez, Monica
Miralles, Pilar
Benito, Jose Miguel
Resino, Salvador
author Jimenez-Sousa, Maria Angeles
author_facet Jimenez-Sousa, Maria Angeles
Rallón, Norma
Berenguer, Juan
Pineda-Tenor, Daniel
López, Juan Carlos
Soriano, Vicente
Guzman-Fulgencio, Maria
Cosín, Jaime
Retana, Diana
Garcia-Alvarez, Monica
Miralles, Pilar
Benito, Jose Miguel
Resino, Salvador
author_role author
author2 Rallón, Norma
Berenguer, Juan
Pineda-Tenor, Daniel
López, Juan Carlos
Soriano, Vicente
Guzman-Fulgencio, Maria
Cosín, Jaime
Retana, Diana
Garcia-Alvarez, Monica
Miralles, Pilar
Benito, Jose Miguel
Resino, Salvador
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Salud Carlos III
RETICS-Sida (RIS-ISCIII) (España)
Fundación para la Investigación y la Prevención del Sida en España
dc.subject.none.fl_str_mv Adult
Alleles
Antiviral Agents
Coinfection
Female
Genotype
HIV Infections
Haplotypes
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
Male
Middle Aged
Multivariate Analysis
Polymorphism, Single Nucleotide
Retrospective Studies
Ribavirin
Toll-Like Receptor 3
topic Adult
Alleles
Antiviral Agents
Coinfection
Female
Genotype
HIV Infections
Haplotypes
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
Male
Middle Aged
Multivariate Analysis
Polymorphism, Single Nucleotide
Retrospective Studies
Ribavirin
Toll-Like Receptor 3
description Background: Toll-like receptor-3 (TLR3) is a cellular receptor that may recognize double-stranded RNA (dsRNA) from viruses, resulting in production of proinflammatory cytokines and interferons, which are important for the adaptive immune response. Objectives: To analyze the association between Toll-like receptor-3 (TLR3) polymorphisms (rs3775291 and rs13126816) and virologic response to pegylated interferon-alpha plus ribavirin (pegIFNα/RBV) therapy in HIV/HCV coinfected patients. Study design: We performed a retrospective study in 321 naïve patients treated with pegIFNα/RBV. Genotyping was performed by using the GoldenGate(®) assay with VeraCode(®). The outcome variables were early virologic response (EVR) and sustained virologic response (SVR). Results: In a multivariate analysis, rs3775291 A allele decreased the likelihood of achieving EVR (aOR = 0.20; p = 0.018) and SVR (aOR = 0.38; p = 0.024). Regarding rs13126816, the percentage of EVR decreased with each minor A allele (p = 0.034) in HCV-GT2/3 patients, although no significant association was obtained in the multivariate analysis (p = 0.076). Regarding TLR3 haplotypes (comprised of rs3775291 and rs13126816), GT2/3 patients with AA haplotype had decreased odds of achieving EVR (p = 0.030), whereas GG haplotype increased the likelihood (p = 0.018). Regarding SVR, GG haplotype carriers had increased odds of achieving SVR (p = 0.019, p = 0.043 and p = 0.070 for all, GT2/3 and GT1/4 patients, respectively). Besides, GT1/4 patients with GA haplotype had lower odds of achieving SVR (p = 0.039). Conclusions: Our study shows the first evidence that two TLR3 polymorphisms (rs3775291 and rs13126816) seem to be related to the HCV therapy response in HCV/HIV coinfected patients.
publishDate 2015
dc.date.none.fl_str_mv 2015
2015-04-01
2015
2015-04-01
2024
2024-05-21
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
AM
http://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/19511
url http://hdl.handle.net/20.500.12105/19511
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422050294104064
score 15.81155

Similares en LA Referencia